Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 8/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31457995 | 0.88 | PREP (0.37) | NR1H2PREPMEN1KMT2ACTSK | |
| SCHEMBL31457946 | 0.86 | PREP (0.38) | NR1H2PREPMEN1KMT2ACTSK | |
| SCHEMBL5649423 | 0.85 | PREP (0.37) | NR1H2PREPCTSKATMCHRM2 | |
| SCHEMBL31048410 | 0.85 | ATM (0.42) | NR1H2MEN1KMT2ACTSKATM | |
| SCHEMBL31457968 | 0.84 | PREP (0.36) | NR1H2PREPMEN1KMT2ACTSK | |
| SCHEMBL6428895 | 0.80 | SRC (0.39) | PREPMEN1KMT2ACTSKATM | |
| SCHEMBL3383660 | 0.80 | NR1H2 (0.38) | NR1H2PREPMEN1KMT2AATM | |
| SCHEMBL24909669 | 0.79 | ALDH1A1 (0.34) | PREPMEN1KMT2ACTSKATM | |
| SCHEMBL30477339 | 0.79 | PREP (0.41) | NR1H2PREPCTSKCHRM2CHRM1 | |
| SCHEMBL26765821 | 0.79 | PREP (0.41) | NR1H2PREPCTSKCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| EP-4172156-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | Philip Morris Products S.A. (CH) | 2023-05-03 | — | — | EP | disclosed |
| CN-115698002-A | Compositions and methods for parasite control | 菲利普莫里斯生产公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021260029-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2021-12-30 | — | — | WO | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2010122151-A1 | 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| WO-2010063663-A1 | N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | TRHDE, CUTA, PIGS | NR1H2 2079/4885PREP 2318/4885MEN1 1738/4885 |
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | NR1H2 1197/4885PREP 4524/4885MEN1 1353/4885 |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | NR1H2 66/4885PREP 2178/4885MEN1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.